| Title | Author(s) | Issue date | ???itemlist.??? |
| Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome | Filippatos, T. D.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Bairaktari, E. T.; Kiortsis, D. N.; Elisaf, M. S. | 24-Nov-2015 | - |
| Apolipoproteins C-Ii and C-Iii and Small Dense Ldl Cholesterol Levels in Non-Diabetic Obese Subjects with Metabolic Syndrome | Filippatos, T.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Tzallas, C.; Bairaktari, E.; Tselepis, A.; Elisaf, M. | 24-Nov-2015 | - |
| Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects | Korantzopoulos, P.; Tzimas, P.; Kalantzi, K.; Kostapanos, M.; Vemmos, K.; Goudevenos, J.; Elisaf, M. S.; Milionis, H. | 24-Nov-2015 | - |
| Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A(2) | Saougos, V. G.; Tambaki, A. P.; Kalogirou, M.; Kostapanos, M.; Gazi, I. F.; Wolfert, R. L.; Elisaf, M.; Tselepis, A. D. | 24-Nov-2015 | - |
| The effect of hypolipidaemic agents on lipoprotein-associated phospholipase A2 (Lp-PLA2) | Saougos, V.; Filippatos, T.; Kostapanos, M.; Kalogirou, M.; Tselepis, A. D.; Elisaf, M. | 24-Nov-2015 | - |
| The effect of hypolipidaemic drugs on lipoprotein- associated phospholipase A2 (Lp-PLA2) activity and mass | Saougos, V.; Kostapanos, M.; Kalogirou, M.; Tselepis, A.; Elisaf, M. | 24-Nov-2015 | - |
| Effect of rosuvastatin on apolipoprotein CII and CIII serum levels in patients with primary dyslipidemia | Kostapanos, M.; Filippatos, T.; Milionis, H.; Kostara, C.; Bairaktari, E.; Elisaf, M. S. | 24-Nov-2015 | - |
| Effect of rosuvastatin on low density lipoprotein (LDL) concentration and relative distribution in patients with primary dyslipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Milionis, H.; Tselepis, A.; Elisaf, M. S. | 24-Nov-2015 | - |
| Effect of rosuvastatin on low density lipoprotein (LDL) profile in patients with primary dyslipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Saougos, V. G.; Milionis, H. J.; Tselepis, A. D.; Elisaf, M. S. | 24-Nov-2015 | - |
| The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome | Filippatos, T. D.; Liberopoulos, E. N.; Kostapanos, M.; Gazi, I. F.; Papavasiliou, E. C.; Kiortsis, D. N.; Tselepis, A. D.; Elisaf, M. S. | 24-Nov-2015 | - |
| The hypertriglyceridaemic waist phenotype as a marker of the atherogenic lipoprotein profile in metabolic syndrome | Gazi, I.; Tsimihodimos, V.; Liamis, G.; Kostapanos, M.; Tselepis, A.; Elisaf, M. S. | 24-Nov-2015 | - |
| Plasma triglyceride levels and body mass index values are the most important determinants of pre beta-1 HDL concentrations in patients with various types of primary dyslipidemia | Tsimihodimos, V.; Gazi, I.; Filippatos, T.; Kostapanos, M.; Lagos, K.; Kostara, C.; Tellis, C. C.; Elisaf, M.; Tselepis, A. D. | 24-Nov-2015 | - |
| Rosuvastatin administration decreases apolipoprotein CII and CIII serum levels in patients with primary dysilipidaemia | Kostapanos, M.; Filippatos, T.; Gazi, I.; Saougos, V. G.; Milionis, H. J.; Kostara, C.; Bairaktari, E.; Elisaf, M. S. | 24-Nov-2015 | - |
| Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome | Filippatos, T. D.; Tsimihodimos, V.; Kostapanos, M.; Kostara, C.; Balraktari, E. T.; Kiortsis, D. N.; Tselepis, A. D.; Elisaf, M. S. | 24-Nov-2015 | - |
| Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) | Milionis, H. J.; Rizos, E.; Kostapanos, M.; Filippatos, T. D.; Gazi, I. F.; Ganotakis, E. S.; Goudevenos, J.; Mikhailidis, D. P.; Elisaf, M. S. | 24-Nov-2015 | - |
